A Study of Real-World Characteristics, Treatment Patterns, and Clinical Outcomes in Patients With Metastatic Castration-Resistant Prostate Cancer
Recruiting · NCT07677254 · Observational (researchers observe without assigning treatment)
View the official record on ClinicalTrials.gov →What this trial is about
The aim of this study is to assess treatment patterns, clinical outcomes, and patient characteristics among adults with metastatic castration-resistant prostate cancer (mCRPC) in the United States (US) real-world clinical practice. This study will be conducted using data extracted from the PRECISION (PRostatE Cancer dISease observatION) data platform.
Who can take part
Age range
18 Years to 115 Years
Sex
Male
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Diagnosis of mCRPC between 01 January 2021 and 31 December 2025.
- Male sex at index, where index is the date of initial mCRPC diagnosis.
- Age 18 years at index.
Exclusion criteria
- None
Where it is running
1 location listed across 1 US state.
- Novartis - East Hanover, New Jersey, United States